PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) has been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $16.67.
Several equities analysts recently weighed in on PHAS shares. Zacks Investment Research lowered shares of PhaseBio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 10th. ValuEngine lowered shares of PhaseBio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of PhaseBio Pharmaceuticals in the fourth quarter valued at approximately $79,000. Tibra Equities Europe Ltd bought a new position in shares of PhaseBio Pharmaceuticals in the first quarter valued at approximately $217,000. United Services Automobile Association bought a new position in shares of PhaseBio Pharmaceuticals in the fourth quarter valued at approximately $286,000. Citigroup Inc. bought a new position in shares of PhaseBio Pharmaceuticals in the fourth quarter valued at approximately $351,000. Finally, Millennium Management LLC bought a new position in shares of PhaseBio Pharmaceuticals in the fourth quarter valued at approximately $411,000. 28.17% of the stock is currently owned by hedge funds and other institutional investors.
PhaseBio Pharmaceuticals (NASDAQ:PHAS) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.03. The business had revenue of $0.26 million for the quarter. On average, sell-side analysts anticipate that PhaseBio Pharmaceuticals will post -2.03 earnings per share for the current fiscal year.
About PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.
Featured Article: Key terms to understand channel trading
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.